Diabetes and Metabolic Research: Reagent Families, Antisera and Immunoassay Kits

Metabolic peptide research draws on three main groups of reagent: islet hormones along with the fragments produced when they are processed; the incretin system, which has reshaped the field over the past decade; and the hepatokines and adipokines that connect liver and adipose tissue to glucose handling. The diabetes topic page collects the immunoassay kits, tracers, antisera and peptide standards that this literature relies on. What follows explains which families the topic contains, the reason each is ordered, and how to match reagent format to the question being asked.

What the diabetes topic covers

A family qualifies for this section if its parent peptide originates in the pancreatic islet, influences how glucose or lipid is handled, or functions as a readout of metabolic state in animal and cell models. That takes in the secretions of beta, alpha, delta and PP cells; the incretins from the gut and the analogues built on them; peptides signalling from liver and fat; and the myokines linking exercise physiology to metabolic phenotyping. There is substantial overlap with the obesity topic — amylin, ghrelin and leptin sit in both — and with cardiovascular research through adrenomedullin and apelin. Every item is supplied for in-vitro use and approved animal studies only.

Hormones of the islet and processing markers

• Insulin — stocked as human, rat, mouse, porcine and bovine sequences, plus proinsulin and analogue standards. Species choice is not a technicality: rodents have two insulin genes, and an assay calibrated on the human hormone will return misleading numbers from rodent samples.
• C-peptide — co-secreted with insulin in equal molar amounts but eliminated more slowly, which makes it the more reliable measure of endogenous output in any model that is also given insulin.
• Glucagon — the alpha-cell hormone opposing insulin. Its assays are notoriously vulnerable to cross-reaction with the other proglucagon-derived peptides, so the specification to scrutinise is antibody selectivity.
• Amylin (IAPP) — released alongside insulin, and also the peptide that forms islet amyloid, so laboratories buy both soluble reference material and preparations able to aggregate.
• Somatostatin and pancreatic polypeptide — the PP-cell and delta-cell products, used both as calibrators and for immunohistochemical mapping of islet composition.
• Preptin — a proIGF-2-derived peptide co-released by beta cells, with a modest but ongoing literature.

The incretin axis

This is where the field is moving quickest, and it is why many laboratories come to the catalog at all:

• GLP-1 — offered as the biologically active (7–36)amide and (7–37) forms, the inactive (9–36) DPP-4 product, and the antagonist exendin(9–39). The whole axis is mapped on the incretin pathway hub.
• GIP — glucose-dependent insulinotropic polypeptide, the other incretin, and now pivotal to the pharmacology of dual agonists.
• Exendin and lixisenatide — the agonist lineage originating in the Gila monster and the clinical molecules descended from it, stocked as reference standards.
• Oxyntomodulin and glicentin — the remaining proglucagon products, where telling them apart from glucagon is the principal analytical challenge.
• GLP-2 — the intestinotrophic relative, studied for intestinal adaptation rather than glucose control.
• Secretin and PYY — gut hormones frequently quantified together with the incretins in nutrient-challenge experiments.

Adipokines, hepatokines and myokines

• Adiponectin — the adipokine that improves insulin sensitivity, supplied as standards and fragments, with the important caveat that the native protein exists in circulation as multimers, which no fragment standard reproduces.
• Leptin and resistin — the original adipokines tying adipose mass to insulin action.
• Ghrelin and obestatin — acylated and unacylated ghrelin differ in activity, and because the octanoyl group is labile, how a sample is handled determines what is actually measured.
• FGF-19 and FGF-23 — the endocrine fibroblast growth factors regulating bile-acid and phosphate handling, both now routine inclusions in metabolic phenotyping panels.
• Betatrophin (ANGPTL8) — claims about beta-cell proliferation were retracted, yet the protein remains an actively studied regulator of lipid metabolism, illustrating neatly that catalog inclusion tracks research use rather than settled biology.
• Irisin and FNDC5 — the myokine induced by exercise and the protein it comes from, an area where antibody specificity has been openly contested in print.
• Visfatin, vaspin and nesfatin — peptides of adipose origin whose literatures cover both appetite and metabolism.
• INSL5 — a colonic enteroendocrine peptide from the relaxin family, of interest in signalling from gut to metabolism.

Formats found in the diabetes topic

Peptide standards serve as calibrators and as agonists or antagonists at receptors. The bulk of the work in this topic, though, is carried by RIA kits and ELISA/EIA kits, because quantifying adipokines, glucagon, GLP-1, C-peptide and insulin in islet supernatant and plasma is everyday practice — and the choice of kit sets the quality of the resulting data. Polyclonal antisera handle Western detection and immunostaining of islets. Labelled peptides provide fluorescent GLP-1 analogues for imaging receptor trafficking and I-125 tracers for classical radioimmunoassay. Multiplex metabolic panels use magnetic beads.

Choosing within a family

Four questions recur. Species is the first and the most consequential: kits standardised against human leptin or insulin will systematically misreport rodent samples, so read the species reactivity for each item. The second is which form of the analyte you want — acylated or unacylated ghrelin, intact or C-terminal FGF-23, total or active GLP-1. Decide the analyte, then choose the kit. Third is cross-reactivity, the source of all the proglucagon family's trouble: an assay that also detects glicentin will overstate glucagon in samples rich in gut peptides. Fourth is kit versus components: if you simply need a concentration from a sample, a validated kit is faster and more reproducible, whereas developing a custom assay, localising a target or probing mechanism calls for the peptide and antibody separately.

Handling notes specific to this topic

Most avoidable failures in this area come from two sources. The first is DPP-4, which degrades active GIP and GLP-1 within minutes in drawn blood, so any plasma intended for an active-form assay needs a DPP-4 inhibitor added at collection — no reagent choice compensates for skipping that step. The second is acyl-ghrelin losing its octanoyl group unless the sample is acidified and given protease inhibitors. Beyond those, the standard rules apply: freeze-dried vials sealed at −20 °C, careful reconstitution, single-use aliquots, and no repeated freeze–thaw. Sequences prone to aggregation, amylin among them, need particular thought about which solvent is used — see peptide solubility, along with the storage guide and the COA guide.

Where to look next

Have a look at the full diabetes topic, the incretin pathway hub or the pancreas and islets hub. You may also want the appetite and obesity section, which shares the adipokine families, and the assay kit type guide when choosing among RIA, EIA and ELISA formats.